Alterola Biotech - ABTI STOCK NEWS

Alterola Biotech (OTC PINK:ABTI) announced its application to upgrade from the OTC PINK to the OTCQB tier of OTC Markets, marking a significant milestone for the company. This upgrade aims to enhance Alterola's visibility in the US and European investment communities, potentially attracting more investors. Executive Chairman Tim Rogers and CEO Seamus McAuley expressed optimism about the upgrade, highlighting opportunities for growth and a broader investor audience. The company focuses on developing cannabinoid and non-cannabinoid pharmaceutical ingredients.

Alterola Biotech Inc. (OTC PINK: ABTI) announced the appointment of Mr. Guy Webber as Preclinical Development Director effective February 1, 2022. With over 25 years in drug metabolism, Webber specializes in ADME and DDI evaluation, particularly in cannabinoid medicines. His experience includes managerial roles at notable pharmaceutical companies and contributions to five successful New Drug Applications. This strategic addition is expected to enhance the company’s capabilities in developing cannabinoid therapies, supporting its commitment to advancing its pipeline.

Alterola Biotech Inc. (OTC PINK:ABTI) has signed a Memorandum of Understanding with Averix Bio LLC for a Good Manufacturing Practice (GMP) supply agreement. This collaboration aims to secure GMP-grade cannabinoids for Alterola’s research and development. Averix Bio operates a facility compliant with cGMP regulations, ensuring quality in manufacturing processes. The GMP-grade Active Pharmaceutical Ingredients (APIs) will support Alterola's existing cannabinoid development projects. Company executives express optimism about this partnership's potential in enhancing pharmaceutical development capabilities.

Alterola Biotech Inc. (OTC PINK:ABTI) announced an agreement to purchase assets from C2 Wellness Corporation for $12 million. The transaction involves issuing 24 million common shares valued at $0.50 each.

The acquisition includes five primary assets related to novel cannabinoid molecules and formulations that enhance Alterola's existing portfolio. The deal has received approval from both companies' boards and involves valuable relationships with academic institutions.

Alterola Biotech Inc. (OTC PINK:ABTI) announced that its Registration Statement on Form S-1 was declared effective by the SEC on October 19, 2021. The company plans to use the net proceeds from the Offering to enhance its research, clinical development programs, and general corporate purposes. Terms of the Offering will be finalized at market pricing. The Prospectus with details on the Offering is available on EDGAR. Investors are urged to review it before making investment decisions. This release does not constitute an offer of any securities.

Alterola Biotech Inc. (OTC PINK: ABTI) announced awareness of promotional activities concerning its common stock around October 12-13, 2021. Articles published by MJ Capital, LLC, and others declared that they received compensation for the promotional campaign. The company distanced itself from these articles and clarified it did not authorize such promotional activities. Additionally, Alterola denied any agreements with the Mina Mar Group regarding an Emerging Growth conference. The company advises investors to rely solely on official communications for accurate information.

Alterola Biotech, Inc. (OTC PINK:ABTI) has reported awareness of promotional activities concerning its common stock, which may have influenced trading. The company was alerted by OTC Markets on October 12, 2021, but remains unaware of specific details regarding the promotion. Alterola emphasizes that it is not affiliated with the promoters and that claims made in promotional materials could be misleading. The company has not engaged any third-party promotional services since January 1, 2021, and all share issuance has been compliant with market rates.

Alterola Biotech Inc (OTC PINK:ABTI) has appointed Hunter Land as a Director effective September 22, 2021. With over 16 years of R&D experience, Land has worked on cannabinoid-focused research and has developed multiple cannabinoid products. Prior roles include being the Sr. Scientific Director at Canopy Growth Corporation and co-authoring protocols for Epidiolex. His appointment is expected to enhance the company’s transition of pipeline candidates from preclinical to clinical development. The Board expressed excitement about his extensive experience and insights.

Alterola Biotech, Inc. has acquired ABTI Pharma Ltd., marking a strategic move into the cannabinoid medicines sector. This acquisition not only changes the company's management team but also expands its portfolio with potential drug candidates and technologies aimed at treating various indications. The CEO highlighted the company’s commitment to developing cannabinoid-based pharmaceuticals, further strengthening its research and development pipeline.